Cogstate
- Short interest
- 0.03%
- 0.00 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 45.9K
- Shares on issue
- 172.126M
Cogstate (CGS) Short Interest
Cogstate (ASX:CGS) had 0.03% of shares reported as short positions as of 8 Oct 2026, representing 45,908 shares. Cogstate operates in the Health Care Equipment & Services industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Cogstate
Cogstate Ltd is a neuroscience company focused on optimizing brain health assessments. They provide digital cognitive assessment tools and services for clinical trials, healthcare, and research, aiming to improve the detection and measurement of cognitive function. Their solutions support the development of new medicines and enable earlier clinical insights in healthcare.
Company profile →Cogstate (ASX:CGS) has 0.03% of its shares on issue reported as short positions as of 8 Oct 2026, or about 45,908 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.81% in July 2023. CGS is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads CGS today
- Zanger BreakoutWatchScore 41rank 207 of 1931
- CAN SLIMWatchScore 23rank 534 of 1541
- Minervini Trend TemplateTriggeredScore 85rank 9 of 1736
- Crowded-Short BreakoutWatchScore 46rank 70 of 1479
- Quality compoundersWatchScore 43rank 194 of 1677
Prices to 13 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
CGS fundamentals
In the year to 30 Jun 2026, Cogstate (ASX:CGS) recorded revenue of US$60.9M and net profit after tax of US$11.9M. A year earlier it recorded revenue of US$53.1M and net profit after tax of US$10.1M. Year-on-year growth: revenue +14.6% (FY). Net margin 19.5% (FY). Figures are in USD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest CGS news
All news- Can Cogstate (ASX:CGS) Sustain Its Trial Contract Momentum?
kalkine · 14 Oct 2026
- Which ASX Growth Stocks With High Insider Ownership Are Worth Watching, Including Cogstate (ASX:CGS)? - Kalkine Media
googlenews · 14 Oct 2026
- 2026 Annual General Meeting Address to Shareholders
asx · 13 Oct 2026
Company details
More Health Care Equipment & Services Stocks
Other shorted stocks in this sector
Be the first to discuss CGS
Start a research thread or post the first pulse update